Vol. 3, No. 6 — June 2026Independent since 2024

TheCompound Journal

Reporting on incretins, compounding & the peptide supply chain

A monthly journal of record.
30 issues · 32 contributors
Not medical advice. We sell nothing.

Sterility

What happens to a stopper after the fourth needle

Particulate matter is the oldest quality attribute in injectable manufacture and the one a private buyer is best placed to assess without instrumentation.

The methods divide into two philosophies. Probabilistic tests — dye ingress, microbial immersion challenge, bubble emission — depend on a chain of events each of which may or may not occur, and their sensitivity is consequently poor and difficult to characterise. Deterministic tests measure a physical quantity: the rate at which a vacuum decays, the current passing through a high-voltage field, the quantity of helium escaping into a mass spectrometer. The compendial guidance has for some years favoured the deterministic family, and a laboratory offering helium leak testing can resolve defects far below the size at which microbial ingress becomes plausible.

Recombinant factor C, and the end of an awkward supply chain

The lysate on which conventional endotoxin testing depends is harvested from horseshoe crabs, which are bled and returned to the sea with a mortality that is disputed and not negligible. The assay also inherits the biological variability of a natural product: lysate lots differ, and the cascade includes a branch responsive to beta-glucans, which is a common source of false positives in the presence of cellulose filter residues.

Recombinant factor C reagents replace the harvested cascade with an expressed enzyme, activated by lipopolysaccharide and read chromogenically or fluorimetrically. The response is specific to endotoxin and insensitive to the glucan branch, lot-to-lot consistency is a manufacturing rather than an ecological question, and comparative studies across a wide range of matrices have found agreement with conventional methods well within the variability of the conventional methods themselves.

The reagent has been available for well over a decade and its slow adoption was a regulatory rather than a scientific matter: for years it sat in an alternative-method chapter, obliging users to validate it as a departure. That has now changed, with dedicated chapters in both the United States and European compendia treating recombinant reagents as methods in their own right, and the Journal expects the harvested lysate to become the historical option within this decade.12

Container closure integrity, method by method

The compendial guidance divides leak test methods into probabilistic and deterministic families and is explicit about preferring the second. Probabilistic methods — dye ingress under vacuum, microbial immersion challenge, bubble emission — rely on a sequence of stochastic events, and their sensitivity is poor and hard to quantify. A dye ingress test can pass a container with a defect large enough to admit an organism, because the dye happened not to travel.

Deterministic methods measure a physical quantity with a continuous response. Vacuum decay monitors pressure rise in an evacuated test chamber. High-voltage leak detection measures current through the container wall and is well suited to liquid-filled units. Laser-based headspace analysis interrogates the gas inside a sealed container non-destructively, which permits repeated measurement of the same unit across a stability programme. Helium mass spectrometry resolves the smallest defects of any method in routine use.

The threshold that matters is the maximum allowable leakage limit — the defect size below which microbial ingress does not occur under the conditions the product will see. Establishing it for a given package is a piece of work, and once established it converts an argument about seals into a measurement.3

The four services have raised the documentation floor of this trade. That is exactly why it matters what their reports do not cover.

Nikolaj Brandvold, Contributing Writer, Sterility

Fourth puncture, fifth puncture: the elastomer as a physical object

A multiple-dose closure is engineered to reseal after a defined number of penetrations by a needle of defined gauge, and the qualification data behind that claim is generated with a specific needle geometry at a specific rate. Beyond that number, the resealing behaviour is not characterised, and the failure is not usually dramatic: the elastomer simply stops closing fully behind the needle track.

Two related phenomena deserve naming. Coring is the removal of a fragment of elastomer by the needle tip, which both leaves a particle in the solution and creates a channel that does not reseal. It is more likely with larger-gauge needles, with repeated penetration through the same point, and with a needle that has already been used and blunted. Fragmentation testing is a compendial requirement for elastomeric closures precisely because of it.

The practical inference available to a reader is not a recommendation, because this publication does not make those. It is an observation about the object: a closure has a puncture budget, that budget is a number somebody determined experimentally, nobody in this trade publishes it, and the elastomer behaves according to the number rather than according to what anybody assumed. Rotating the entry point and using a fresh needle each time are answers to a mechanical problem, not to a microbiological one.

What twenty companies answered on five sterility questions
QuestionAnsweredDeclinedNo reply
Fill route: aseptic or terminal947
Pre-filtration bioburden determined749
Filter integrity tested post-use5411
Aseptic process simulation performed3512
Endotoxin determined on finished product4412
Questions were sent twice, four weeks apart, to the published contact address of each company. Declined denotes a reply that engaged with the question and refused it; no reply denotes two unanswered messages. Four of the declines cited the research-use-only basis of sale, which the Journal regards as a legally sound answer.

Particulate matter, visible and subvisible

Injectable products are required to be essentially free of visible particulates, and every container in a regulated batch is inspected against dark and light backgrounds under defined illumination. The detection threshold for a trained inspector is somewhere near fifty microns for a contrasting particle, and the inspection is a hundred per cent operation rather than a sample-based one, which makes it unusual among quality tests.

Subvisible particles are counted instrumentally. Light obscuration is the primary compendial method, with microscopic membrane counting as the alternative when the sample defeats it. For a small-volume injection the limits are six thousand particles at or above ten microns and six hundred at or above twenty-five microns per container. Products that are themselves proteinaceous get a distinct chapter, because inherent aggregates complicate the counting and the method has to distinguish them from extrinsic contamination.

For a private buyer, visible inspection is the one quality operation available without instrumentation, and it is worth doing carefully: a lyophilised cake that has collapsed to a glassy disc, a reconstituted solution showing a faint tyndall haze on rotation, a fibre against a dark card. None of those is a sterility finding. All of them are evidence about how the product was made and how it has travelled.45

What the cake tells you

A lyophilised plug is a physical record of the cycle that produced it. A well-formed cake occupies close to the volume of the solution that was frozen, has a matte, uniform appearance, retains a defined edge where it met the glass, and dissolves rapidly and completely on addition of diluent. That appearance indicates that the product was frozen below its critical formulation temperature and dried without the structure collapsing.

Departures are informative. A shrunken, translucent or glassy plug suggests collapse during primary drying — the ice sublimed faster than the amorphous matrix could hold its structure — which is associated with higher residual moisture and a shorter shelf life. A cake that has partly detached and moves freely suggests mechanical handling after drying, which is cosmetic. A cake showing melt-back at the base, or a visible meniscus line, suggests a shelf temperature excursion. Slow or incomplete reconstitution suggests either collapse or an unfavourable surface.

None of these observations is a purity finding, a sterility finding or an endotoxin finding, and it is important not to overclaim. What they are is the only direct evidence about process control that arrives in the box, and reading them costs nothing. The Journal photographs every cake it receives before opening the vial, for exactly that reason.6

111805019-1210 containers20 containers100 containers0.10.512510true contamination rate (% of containers)probability the batch passes (%)
Figure. Probability that the compendial sterility test passes a batch, as a function of true contamination rate, for three sample sizes. The twenty-container sample required for a batch above five hundred units is the middle series.

Five lines that would change what a certificate is worth

Nothing the Journal asks for here requires a regulator, an inspectorate or a change in the law, and none of it is commercially sensitive. All five items are already known to whoever released the batch.

First, state the fill route: aseptic or terminal, and if aseptic, in what class of environment. Second, state the pre-filtration bioburden result against its specification, or state that bioburden is not determined. Third, state whether the sterilising filter was integrity-tested after use. Fourth, report bacterial endotoxin per milligram of peptide, with the method and the inhibition-enhancement result, or state that it was not determined. Fifth, where a sterility test has been performed, state the batch size, the number of containers tested and the method, so that a reader can do the arithmetic in the section above. Every one of the five is an ordinary element of a release specification for a biological product, and none of them is an invention of this publication.7

A certificate carrying those five lines would remain a one-page document and would be worth several times what the current one is worth, principally because four of the five lines are permitted to say no. A stated negative is a fact a reader can use. An omission is a space a reader fills with an assumption, and the assumption is always more favourable than the truth would have been.

What this article is not asserting

Precision about the scope of a criticism is part of the job, so it is worth spending a paragraph on what is not being said. This piece does not allege that any company named in it has sold contaminated material. It does not allege that any of them has concealed a result, falsified a document or misrepresented a test. It does not claim that the products discussed are dangerous, and it does not claim that they are safe, because neither claim is supportable from the evidence we have.

What the piece asserts is documentary. A certificate describing chemistry is being read as a release package covering microbiology. That mismatch is created by the format of the document rather than by anybody’s intent, and it is closed by adding lines rather than by changing behaviour.

There is also a legal point the Journal has no wish to elide. Research-use-only material is not approved for human use in any jurisdiction, is not required to meet parenteral standards, and is not represented by its sellers as meeting them. Everything in this article about endotoxin limits and sterility assurance describes the framework that would apply to a parenteral medicine. Applying that framework to a research chemical is a comparison, not a compliance requirement, and readers should hold both halves of that sentence at once.

Killing the bacteria does not remove the endotoxin, and may increase the free concentration.

A note on method and sourcing

The compendial material in this article is drawn from the current general chapters of the United States Pharmacopeia and the European Pharmacopoeia, read in the original rather than in summary, and from the international standards on aseptic processing and on laboratory competence. Where a chapter has changed status recently — as the recombinant reagent chapters have — we say so, because a reader consulting an older edition will find a different framing.

Where the Journal reports a number it obtained itself, it states the laboratory’s accreditation status, the method family, whether method suitability was established, and the number of determinations. Where we report what a company told us, we distinguish an answer from a refusal and a refusal from a non-response, because those three things are routinely collapsed in coverage of this trade and they are not the same.

Corrections to this department are handled by the standards desk, which reads every letter and records the outcome in the log. Readers who believe a paragraph here overstates its evidence are asked to write to standards@compoundjournal.com; readers with documents to send, including certificates they would like read, should write to letters@compoundjournal.com. We do not publish correspondents’ names without permission and we do not identify the source of a certificate.

Five determinations: method, sample fate and what a private buyer pays
DeterminationMethod familySampleTurnaroundRelative cost
PurityReversed-phase HPLC, UVA few mg, non-destructive to batch2–7 days
IdentityLC–MS, optionally MS/MSA few mg3–10 days1–2×
Peptide contentElemental N or quantitative AAASeveral mg2–4 weeks2.5–3×
Bacterial endotoxinKinetic chromogenic LAL or rFC<1 mL reconstituted3–10 days2–3×
SterilityMembrane filtration, 14-day incubationEntire container, destroyed3–4 weeks6–10×
Relative cost is expressed against a single generic-gradient purity run as 1×, from quotations obtained by the Journal from contract laboratories during the year. Sterility pricing assumes a single container rather than a compendial sample of twenty.

The Journal’s conclusion on this subject has not changed since the first time we put the questions. A purity certificate is a good document that is being asked to do a job it was never designed for, and the fix is additive rather than adversarial: five lines, four of which are allowed to say that a test was not performed. Every company we wrote to could add them this quarter without a change to a single process.

References

  1. United States Pharmacopeia. General Chapter ⟨86⟩ Bacterial Endotoxins Test Using Recombinant Reagents. USP–NF, Rockville, MD.
  2. European Pharmacopoeia. Chapter 2.6.32 — Test for Bacterial Endotoxins Using Recombinant Factor C. Council of Europe, Strasbourg.
  3. United States Pharmacopeia. General Chapter ⟨1207⟩ Package Integrity Evaluation — Sterile Products. USP–NF, Rockville, MD.
  4. United States Pharmacopeia. General Chapter ⟨788⟩ Particulate Matter in Injections. USP–NF, Rockville, MD.
  5. United States Pharmacopeia. General Chapter ⟨787⟩ Subvisible Particulate Matter in Therapeutic Protein Injections. USP–NF, Rockville, MD.
  6. “Cake appearance, collapse temperature and residual moisture in lyophilised peptide formulations.” AAPS PharmSciTech. 2019;20(7):286.
  7. International Council for Harmonisation. Q6B: Specifications — Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. 1999.

Letters to the Editor

4 printed

Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.

A quibble about depyrogenation. You imply an operation describing autoclaving alone has skipped a step, but depyrogenation of glass is only necessary if the incoming glass carries endotoxin. Vials supplied ready-to-use from a component manufacturer arrive already depyrogenated and certified as such.

J. Mbatha, Durban

The Journal replies

Correct, and the text now says so. A ready-to-use component with a certificate stating its endotoxin limit is a perfectly good answer to the question; what is not an answer is autoclaving ordinary glass and describing the result as pyrogen-free.

The statistics section is the part of this I will be sending to people. I had assumed a passed sterility test meant something about the batch. It had not occurred to me that a batch with one contaminated vial in a hundred passes four times out of five.

L. Whitcombe, Christchurch

You keep saying you are criticising documentation and not honesty. I think that distinction is doing more work than it can bear. If a company knows buyers read a purity certificate as a safety document and issues one anyway, the omission is doing something.

J. Kettleborough, Nottingham

The Journal replies

It is a fair challenge and we have thought about it. Our answer is that the convention long predates any individual company’s decision to follow it, that four of our correspondents told us plainly the products are not represented as sterile injectables, and that we have no evidence of anybody intending the inference readers draw. We will report intent when we can demonstrate it and not before.

I photograph every cake now because of an earlier piece of yours, and last month it paid for itself. Two vials from the same box, one a proper matte plug and one a collapsed glassy disc. The supplier replaced both without argument when I sent the photographs.

C. Nightingale, Plymouth

Related coverage